• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Kenvue Inc.

    5/7/25 3:31:35 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary
    Get the next $KVUE alert in real time by email
    DEFA14A 1 kenvue-proxysupplement.htm DEFA14A Document



    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 14A INFORMATION
    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934

    ☑
    Filed by the Registrant
    ☐
    Filed by a Party other than the Registrant

    Check the appropriate box:
    ☐
    Preliminary Proxy Statement
    ☐
    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐
    Definitive Proxy Statement
    ☑
    Definitive Additional Materials
    ☐
    Soliciting Material under Rule 14a-12
    Kenvue Inc.
    (Name of registrant as specified in its charter)
    (Name of person(s) filing proxy statement, if other than the registrant)

    Payment of Filing Fee (Check all boxes that apply):
    ☑
    No fee required
    ☐
    Fee paid previously with preliminary materials
    ☐
    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11















    SUPPLEMENT TO DEFINITIVE PROXY STATEMENT DATED MAY 7, 2025
    FOR THE 2025 ANNUAL MEETING OF STOCKHOLDERS

    This proxy statement supplement, dated May 7, 2025 (this “Supplement”), amends and restates the disclosure in the Definitive Proxy Statement (the “Proxy Statement”) of Kenvue Inc. (the “Company”) for the 2025 Annual Meeting of Stockholders (the “Annual Meeting”), filed with the Securities and Exchange Commission on April 9, 2025, under the heading “Certain Related Persons Transactions with Directors” relating to a description of certain relationships between the Company, directors and certain third parties (the “Supplemental Disclosure”). The Supplemental Disclosure should be read in conjunction with the Proxy Statement.
     
    The Supplemental Disclosure does not change the proposals to be acted on at the Annual Meeting or the recommendation of the Board of Directors with respect to any proposals. Except as specifically amended and restated by the Supplemental Disclosure contained herein, this Supplement does not revise or update any of the other information set forth in the Proxy Statement. This Supplement does not provide all of the information that is important to your voting decisions at the Annual Meeting, and the Proxy Statement contains other important additional information. Capitalized terms used in the Supplemental Disclosure and not otherwise defined herein have the meanings given to them in the Proxy Statement.
     
    The information under the heading “Certain Related Persons Transactions with Directors” on page 95 of the Proxy Statement is amended and restated to read as follows:

    Ms. Hofstetter is the president of Profitero, Ltd. (“Profitero”), a subsidiary of Publicis Groupe S.A. (“Publicis”). Kenvue paid Profitero approximately $1.2 million in 2024 in connection with ordinary course business transactions involving market data analytics, which represented substantially less than 2% of Publicis’ 2024 consolidated gross revenues. The transactions involved Profitero gathering and analyzing data from public sources including retailer websites, marketplaces and search results on a subscription basis and relaying such analysis to Kenvue and did not involve providing Profitero access to any sensitive information of Kenvue or access to any of Kenvue’s strategic decision-making. Payments to Profitero consisted of a pre-agreed fixed price for a subscription to market data analytics and were not made under a commission- or fee-based payment structure. Accordingly, Kenvue does not consider such services to be advisory in nature or material. As discussed in “Corporate Governance—Director Independence”, our Board has assessed the independence of Ms. Hofstetter and affirmatively determined that she qualifies as “independent” in accordance with the listing standards of the NYSE and the heightened requirements under our “Standards of Independence” in our Principles of Corporate Governance.

    Mr. Perry was the president and CEO of Circana, Inc. until December 2024. Kenvue paid Circana approximately $7.6 million in 2024 for transactions involving consumer data, analytics, and insights services.

    These transactions were provided to Kenvue on an arm’s-length basis on terms that are substantially equivalent to those prevailing at the time for comparable transactions and neither Ms. Hoffstetter nor Mr. Perry had or have a role in Kenvue’s decision making with respect to which firms to utilize for these matters.    


    Get the next $KVUE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KVUE

    DatePrice TargetRatingAnalyst
    1/30/2026$18.00Buy → Hold
    Jefferies
    10/29/2025$15.00Buy → Hold
    Canaccord Genuity
    9/26/2025$22.00Neutral → Buy
    Rothschild & Co Redburn
    4/10/2025$23.50Neutral
    Redburn Atlantic
    3/24/2025$25.00In-line
    Evercore ISI
    1/6/2025$21.00 → $26.00Neutral → Overweight
    Piper Sandler
    12/12/2024$25.00 → $24.00Buy → Hold
    Deutsche Bank
    9/24/2024$27.00Buy
    Jefferies
    More analyst ratings

    $KVUE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kenvue to Announce Fourth Quarter and Full Year 2025 Results on February 17, 2026

    Kenvue Inc. (NYSE:KVUE) will announce its fourth quarter and full year 2025 financial results after market close on February 17, 2026. Due to the pending transaction with Kimberly-Clark, Kenvue will not be hosting a quarterly conference call to review its financial results. The press release will be available on the company's website at investors.kenvue.com. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue,

    2/4/26 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kimberly-Clark and Kenvue Shareholders Overwhelmingly Approve Kimberly-Clark's Acquisition of Kenvue

    Key Milestone in Creating a Global Health and Wellness Leader Transaction Expected to Close in the Second Half of 2026 DALLAS and SUMMIT, N.J., Jan. 29, 2026 /PRNewswire/ -- Kimberly-Clark Corporation (NASDAQ:KMB) and Kenvue Inc. (NYSE:KVUE) today announced that Kimberly-Clark and Kenvue shareholders voted overwhelmingly to approve all of the proposals necessary for Kimberly-Clark to complete its acquisition of Kenvue at their respective Special Meetings of Stockholders held today. "We are grateful to Kimberly-Clark shareholders who voted resoundingly in support of our combina

    1/29/26 9:27:00 AM ET
    $KMB
    $KVUE
    Containers/Packaging
    Consumer Discretionary
    Specialty Chemicals

    Kenvue Declares Quarterly Cash Dividend

    Kenvue Inc. (NYSE:KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock. The quarterly dividend is payable on February 25, 2026, to shareholders of record as of the close of business on February 11, 2026. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that po

    1/28/26 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief People Officer Alvarado Luani exercised 85,534 shares at a strike of $13.76 and covered exercise/tax liability with 71,581 shares, increasing direct ownership by 43% to 46,602 units (SEC Form 4)

    4 - Kenvue Inc. (0001944048) (Issuer)

    2/10/26 4:19:38 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    SEC Form 3 filed by new insider Curado Gomes De Lemos Leonardo

    3 - Kenvue Inc. (0001944048) (Issuer)

    1/12/26 5:16:49 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    SEC Form 4 filed by Chief Financial Officer Banati Amit

    4 - Kenvue Inc. (0001944048) (Issuer)

    1/6/26 4:39:35 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Smith Jeffrey C bought $110,986,526 worth of shares (6,377,694 units at $17.40) (SEC Form 4)

    4 - Kenvue Inc. (0001944048) (Issuer)

    12/15/25 4:00:25 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    SEC Filings

    View All

    Kenvue Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Kenvue Inc. (0001944048) (Filer)

    1/29/26 4:30:38 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    SEC Form 425 filed by Kenvue Inc.

    425 - Kenvue Inc. (0001944048) (Subject)

    1/27/26 5:21:22 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    SEC Form 425 filed by Kenvue Inc.

    425 - Kenvue Inc. (0001944048) (Subject)

    1/16/26 5:29:28 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Kenvue downgraded by Jefferies with a new price target

    Jefferies downgraded Kenvue from Buy to Hold and set a new price target of $18.00

    1/30/26 6:43:10 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Kenvue from Buy to Hold and set a new price target of $15.00

    10/29/25 7:19:36 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue upgraded by Rothschild & Co Redburn with a new price target

    Rothschild & Co Redburn upgraded Kenvue from Neutral to Buy and set a new price target of $22.00

    9/26/25 8:00:14 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Financials

    Live finance-specific insights

    View All

    Kenvue to Announce Fourth Quarter and Full Year 2025 Results on February 17, 2026

    Kenvue Inc. (NYSE:KVUE) will announce its fourth quarter and full year 2025 financial results after market close on February 17, 2026. Due to the pending transaction with Kimberly-Clark, Kenvue will not be hosting a quarterly conference call to review its financial results. The press release will be available on the company's website at investors.kenvue.com. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue,

    2/4/26 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue Declares Quarterly Cash Dividend

    Kenvue Inc. (NYSE:KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock. The quarterly dividend is payable on February 25, 2026, to shareholders of record as of the close of business on February 11, 2026. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that po

    1/28/26 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kimberly-Clark to Acquire Kenvue, Creating a $32 Billion Global Health and Wellness Leader

    Combines Highly Complementary and Strategically Aligned Consumer Offerings, Including 10 Iconic Billion-Dollar Brands, That Will Provide Preferred Solutions Through Every Stage of Life Applies Kimberly-Clark's Proven Commercial Execution Playbook to Create a Best-in-Class Consumer-Driven Company Accelerates Kenvue's Premier Consumer Health Portfolio and Strong Science-Backed Innovation, Supported by Talented Kenvue Team Enhances Investment in Marketing, Innovation and R&D Capabilities to Strengthen Combined Company's Unique Advantages Total Anticipated Run-Rate Synergies of $2.1 Billion; Expected to Be Accretive to Kimberly-Clark's Adjusted EPS By Year 2 Delivers Immediate Upfront Value to K

    11/3/25 6:30:00 AM ET
    $KMB
    $KVUE
    Containers/Packaging
    Consumer Discretionary
    Specialty Chemicals

    $KVUE
    Leadership Updates

    Live Leadership Updates

    View All

    Kenvue Announces CEO Transition and Actions to Unlock Shareholder Value

    Appoints Current Kenvue Director and Proven CPG and Technology Company Leader, Kirk Perry, as Interim CEO, Effective Immediately Announces Ongoing Review of Strategic Alternatives Reports Select Preliminary Second Quarter 2025 Financial Results Kenvue Inc. (NYSE:KVUE) today announced that its Board of Directors is implementing a set of actions to enable the Company to unlock shareholder value and reach its full potential. The Board has made a Chief Executive Officer transition and is advancing an ongoing comprehensive review of strategic alternatives. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250714520711/en/Kirk

    7/14/25 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue Debuts on Fortune 500 List

    Kenvue Inc. (NYSE:KVUE), maker of consumer health products like Tylenol®, Neutrogena® and Listerine®, today announced it has made the prestigious Fortune 500 list for the first time since becoming a fully independent company. With 2024 full year sales of $15.5 billion, Kenvue is listed at number 281. The company's debut is a testament to the power of its iconic brands and deep commitment to improving the health and well-being of consumers globally through science-backed, insights-led innovation. "Being named to the Fortune 500 list marks a significant milestone for Kenvue," said Thibaut Mongon, Chief Executive Officer. "Recognitions like this validate the hard work and dedication of our K

    6/2/25 6:15:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue Announces Chief Financial Officer Transition

    Amit Banati, 30-Year Consumer Products Company Finance and Operations Veteran, Appointed CFO Succeeds Paul Ruh, Effective May 12, 2025 Kenvue Inc. (NYSE:KVUE), today announced the appointment of Amit Banati as the Company's Chief Financial Officer, effective May 12, 2025. He will be responsible for overseeing the Finance and Strategy functions, supporting initiatives aimed at accelerating profitable growth and delivering value to shareholders. Following a thorough and thoughtful search process, Mr. Banati will succeed Paul Ruh, who will remain with the Company for a brief period to help ensure a smooth transition. Mr. Banati is a 30-year consumer products company finance and operation

    5/8/25 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

    SC 13G/A - Kenvue Inc. (0001944048) (Subject)

    11/14/24 1:22:40 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

    SC 13G/A - Kenvue Inc. (0001944048) (Subject)

    11/12/24 10:32:12 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

    SC 13G/A - Kenvue Inc. (0001944048) (Subject)

    10/16/24 10:07:52 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary